Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 1
2013 1
2014 3
2016 3
2017 5
2018 3
2019 2
2020 5
2021 3
2022 3
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Are phase I trials safe for older patients?
Baldini C, Le Saux O, Helissey C, Aspeslagh S, Castanon E, Varga A, Gazzah A, Bahleda R, Mir O, Massard C, Soria JC, Hollebecque A. Baldini C, et al. Among authors: bahleda r. J Geriatr Oncol. 2018 Mar;9(2):87-92. doi: 10.1016/j.jgo.2017.08.012. Epub 2017 Sep 8. J Geriatr Oncol. 2018. PMID: 28890328 Review.
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
Assi T, Ngo C, Faron M, Verret B, Lévy A, Honoré C, Hénon C, Le Péchoux C, Bahleda R, Le Cesne A. Assi T, et al. Among authors: bahleda r. Curr Treat Options Oncol. 2023 Nov;24(11):1598-1613. doi: 10.1007/s11864-023-01139-3. Epub 2023 Oct 16. Curr Treat Options Oncol. 2023. PMID: 37843627 Review.
Antibody drug conjugates in older patients: State of the art.
Rached L, Geraud A, Frelaut M, Ap Thomas Z, Goldschmidt V, Beraud-Chaulet G, Nagera-Lazarovici C, Danlos FX, Henon C, Parisi C, Gazzah A, Bahleda R, Postel Vinay S, Smolenschi C, Hollebecque A, Michot JM, Ribrag V, Loriot Y, Champiat S, Ouali K, Massard C, Ponce Aix S, Bringuier M, Baldini C. Rached L, et al. Among authors: bahleda r. Crit Rev Oncol Hematol. 2024 Jan;193:104212. doi: 10.1016/j.critrevonc.2023.104212. Epub 2023 Nov 24. Crit Rev Oncol Hematol. 2024. PMID: 38007063 Review.
Electrolyte disorders related to EGFR-targeting drugs.
Izzedine H, Bahleda R, Khayat D, Massard C, Magné N, Spano JP, Soria JC. Izzedine H, et al. Among authors: bahleda r. Crit Rev Oncol Hematol. 2010 Mar;73(3):213-9. doi: 10.1016/j.critrevonc.2009.03.012. Epub 2009 Apr 28. Crit Rev Oncol Hematol. 2010. PMID: 19403315 Review.
PALLIA 10 score in phase I cancer studies.
Ouali K, Mateus C, Laparra A, Martin Romano P, Sampetrean A, Vuagnat P, Varga A, Champiat S, Verlingue L, Geraud A, Marabelle A, Hollebecque A, Gazzah A, Bahleda R, Postel Vinay S, Michot JM, Bernard-Tessier A, Bayle A, Ribrag V, Soria JC, Scotte F, Massard C, Pavliuc E, Baldini C. Ouali K, et al. Among authors: bahleda r. BMJ Support Palliat Care. 2022 Aug 30:bmjspcare-2022-003601. doi: 10.1136/spcare-2022-003601. Online ahead of print. BMJ Support Palliat Care. 2022. PMID: 36041820
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. Levy A, et al. Among authors: bahleda r. Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. Mol Cancer. 2024. PMID: 38519913 Free PMC article. Clinical Trial.
Patterns of progression in patients treated for immuno-oncology antibodies combination.
Bernard-Tessier A, Baldini C, Castanon E, Martin P, Champiat S, Hollebecque A, Postel-Vinay S, Varga A, Bahleda R, Gazzah A, Michot JM, Ribrag V, Armand JP, Marabelle A, Soria JC, Massard C, Ammari S. Bernard-Tessier A, et al. Among authors: bahleda r. Cancer Immunol Immunother. 2021 Jan;70(1):221-232. doi: 10.1007/s00262-020-02647-z. Epub 2020 Jul 22. Cancer Immunol Immunother. 2021. PMID: 32700090 Free PMC article. Clinical Trial.
Epigenetic gene alterations in metastatic solid tumours: results from the prospective precision medicine MOSCATO and MATCH-R trials.
Martin-Romano P, Colmet-Daage L, Morel D, Baldini C, Verlingue L, Bahleda R, Gazzah A, Champiat S, Varga A, Michot JM, Ngo-Camus M, Nicotra C, Marabelle A, Soria JC, Rouleau E, Lacroix L, Hollebecque A, Massard C, Postel-Vinay S. Martin-Romano P, et al. Among authors: bahleda r. Eur J Cancer. 2022 Sep;173:133-145. doi: 10.1016/j.ejca.2022.06.014. Epub 2022 Jul 21. Eur J Cancer. 2022. PMID: 35872509
Sustained cancer clinical trial activity in a French hospital during the first wave of the COVID-19 pandemic.
Bayle A, Baldini C, Martin-Romano P, Michot JM, Champiat S, Bahleda R, Gazzah A, Marabelle A, Verlingue L, Geraud A, Morel D, Michiels S, Hollebecque A, Albiges L, Besse B, Soria JC, Massard C, Barlesi F, Postel-Vinay S. Bayle A, et al. Among authors: bahleda r. Cancer Cell. 2021 Aug 9;39(8):1039-1041. doi: 10.1016/j.ccell.2021.06.010. Epub 2021 Jun 18. Cancer Cell. 2021. PMID: 34197735 Free PMC article. No abstract available.
29 results